Reducing complications of liver failure in patients with decompensated liver cirrhosis. Congenital cirrhosis (of liver)
Conditions
Interventions
Intervention 1: Intervention group: In the intervention group, after selecting the patients, a sample of mesenchymal stem cells is injected intravenously at the rate of 1 million per kilogram of body
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Having clinical and laboratory manifestations related to uncompensated liver cirrhosis Age between 18 and 65 years Absence of pregnancy in women There is no specific treatment for cirrhosis Consent to participate in the study
Exclusion criteria
Exclusion criteria: Having an underlying malignancy Evidence of extrahepatic biliary diseases Active thrombosis in the hepatic or portal vein Respiratory or kidney failure Active infection Liver transplantion candidate patients Patients with diabetes mellitus Patients with severe cardiovascular disease and high blood pressure not controlled by medication The presence of severe underlying diseases pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Check liver function. Timepoint: At intervals of 3 and 6 months after injection. Method of measurement: Examining the laboratory parameters of the patient related to the liver with a laboratory device.;Evaluation of the Child-pugh criterion. Timepoint: 3 and 6 months after injection. Method of measurement: Completing certain questionnaires according to laboratory and clinical results of patients.;Evaluation of the MELD criterion. Timepoint: 3 and 6 months after injection. Method of measurement: Completing certain questionnaires according to laboratory and clinical results of patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Farsinejad
Kerman University of Medical Sciences
Outcome results
None listed